AEV103 (3,6’-dithiopomalidomide), a potentially immunomodulating medicine, was able to quell brain inflammation and slow cognitive decline in a mouse model of Alzheimer’s disease, a study has found. The medicine, developed originally at the National Institutes of Health (NIH) and now licensed to AevisBio, exerted its effects even in the absence of any change in the levels of amyloid-beta, the protein that clumps together to form the toxic deposits that cause the death of nerve cells…
You must be logged in to read/download the full post.
The post AEV103 Can Quell Brain Inflammation, Slow Cognitive Decline in Mice appeared first on BioNewsFeeds.